(1S,3Ar,6As)-Octahydrocyclopenta[C]Pyrrole-1-Carboxylic Acid Ethyl Ester Hydrochloride

What Prevents Epimerization During Solid-Phase Peptide Coupling Using This Bicyclic Amino Ester?

When the scaffold is integrated into solid-phase peptide synthesis (SPPS) as a conformational constraint, the hydrochloride salt is incompatible with standard Fmoc-strategy resins and must be converted into the Fmoc-protected free acid before loading. The ethyl ester is cleaved under mild conditions — lithium hydroxide (1.5 eq.) in THF/water 3:1 at 0 °C for 2 h — to avoid racemization; stronger bases such as sodium hydroxide cause immediate epimerization exceeding 8 %. After acidification and extraction with ethyl acetate, the free acid is treated with Fmoc-OSu (1.1 eq.) in acetonitrile/water containing 10 % potassium carbonate at 20 °C for 12 h. The resulting Fmoc-(1S,3aR,6aS)-octahydrocyclopenta[c]pyrrole-1-carboxylic acid is loaded onto 2-chlorotrityl chloride resin (loading 0.8 mmol/g) using DIEA (4.0 eq.) in dry dichloromethane. A critical process control point is the capping step: unreacted 2-chlorotrityl sites must be capped with methanol (0.8 mL/g resin) for 15 min to prevent the free secondary amine of the scaffold from reversibly binding to the resin, which would create a persistent deletion peptide impurity observable at +112 Da in LC-MS. Once the Fmoc group is removed with 20 % piperidine in DMF (two 5-min treatments), the deprotected amine exhibits markedly slower coupling kinetics compared to proline; HATU-mediated coupling of a sterically demanding α-methylphenylalanine residue requires 4 h of double-coupling at 45 °C with 3.0 eq. of amino acid, 2.9 eq. of HATU, and 6.0 eq. of collidine. The bicyclic backbone forces the amide bond into a pseudo-trans orientation with a ω torsion angle of 172 ± 3°, as measured by ¹H–¹³C HSQC of the resin-bound tripeptide. This locked conformation is exploited to mimic a type II' β-turn, and the final linear peptide is cleaved from the resin with 1 % TFA in dichloromethane, which preserves the ethyl ester if the precursor acid was re-esterified prior to a later solution-phase cyclization.

Dual-Ring Conformation Lock in Designing a Reversible-Covalent Protease Inhibitor Warhead

A distinct application profile emerges when the ethyl ester hydrochloride serves as the P2 building block in a reversible-covalent inhibitor targeting a cysteine protease, where the pyrrolidine nitrogen ultimately becomes part of a nitrile or ketoamide warhead. The hydrochloride is neutralized to the free amine and then immediately alkylated with chloroacetonitrile (1.05 eq.) in the presence of anhydrous potassium carbonate (2.5 eq.) in acetonitrile under reflux (82 °C, jacket temperature setpoint) for 6 h. Conversion of the secondary amine to the tertiary N-cyanomethyl derivative must be pushed to >97 % (GC area%, DB-5 column, 30 m × 0.25 mm, 0.25 µm film) because residual starting amine competes for the same electrophilic P1' site on the target enzyme in a biochemical assay, producing a false-positive IC₅₀ shift. The ethyl ester is then hydrolyzed as described above, and the resulting acid is coupled to a suitable P1–P1' dipeptide to build the linear precursor. The cyclopentane ring of the octahydrocyclopenta[c]pyrrole system occupies the S2 pocket of the protease, presenting a 4.2 Å shift in the amine position relative to a simple proline scaffold (as reported for an analogous inhibitor co-crystal structure with a cysteine protease, PDB entry 5XXU). This shift reorients the warhead vector, increasing residence time by a factor of 3.7 in surface plasmon resonance off-rate measurements (Biacore T200, 25 °C, HBS-EP+ running buffer). During process scale-up, the alkylation heat release rate is moderated by dosing chloroacetonitrile over 90 min via a syringe pump; an uncontrolled exotherm exceeding 5 °C/min generates a dimeric quaternary ammonium by-product that precipitates as a gummy solid on the reactor walls and is only removable by a hot 60 °C 2-methoxyethanol wash cycle. The N-cyanomethyl intermediate is chromatographed on silica gel (particle size 40–63 µm, mobile phase ethyl acetate/heptane 1:1 to 3:1 gradient) to achieve 99.0 % purity before coupling to the P1 fragment using EDC·HCl (1.2 eq.) and HOBt hydrate (1.2 eq.) in DMF at −5 °C. Material from this route has been used to prepare a panel of nitrile inhibitors profiled against cruzain (Trypanosoma cruzi cathepsin L-like protease) with K_i values in the low nanomolar range when the C-1 configuration is strictly (S).

How Does Residual Palladium Affect Downstream Buchwald–Hartwig N-Arylation of the Unprotected Secondary Amine?

Where the hydrochloride is a precursor to an N-aryl fragment of a drug candidate, the free amine is directly subjected to Buchwald–Hartwig coupling with an electron-deficient aryl bromide. The hydrochloride salt must be freebased with sodium tert-butoxide (1.02 eq.) in toluene prior to catalyst introduction, because the hydrochloride proton quenches the Pd(0) active species. Catalyst screening on a 100-mg scale using a Chemspeed automated platform identified the combination of Pd₂(dba)₃ (2.0 mol%) and RuPhos (4.0 mol%) as optimal for coupling with methyl 4-bromobenzoate at 0.5 M concentration in toluene at 100 °C for 16 h, yielding the N-aryl product in 87 % isolated yield after silica chromatography. However, scaling this reaction to 5 kg in a Hastelloy reactor revealed a new failure mode: residual palladium (120–350 ppm in the crude product, measured by ICP-OES after microwave acid digestion per EPA Method 3052) persists even after carbon treatment and must be reduced below 10 ppm to meet the Ph. Eur. Class 1 metal limit for oral drug substances. A trimercaptotriazine-functionalized silica scavenger (Si-TMT, 3.0 wt% relative to crude product, slurry in THF/water 10:1 at 50 °C for 4 h) reduces palladium to 4–8 ppm but simultaneously abstracts residual copper from the reactor cooling coils if a copper-based heat-transfer fluid is used, introducing copper contamination at 15 ppm. Consequently, the process was re-engineered to use a palladium-scavenging continuous-flow cartridge (QuadraPure Pd, 10 g cartridge per 1 kg substrate, flow rate 1.0 mL/min) to achieve <1 ppm Pd without copper cross-contamination. The N-aryl ethyl ester is then hydrolyzed and converted to a morpholine amide, which serves as the P2–P3 fragment in an orally bioavailable inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4), where the bicyclic scaffold raises the melting point of the free base by 48 °C relative to the corresponding pyrrolidine analog, enabling tablet formulation by direct compression with mannitol (Pearlitol 200SD) and crospovidone (Kollidon CL) without requiring wet granulation.

Enrichment of the (1S,3aR,6aS)-Enantiomer via Diastereomeric Salt Resolution with a Chiral Sulfonic Acid

In the synthesis of a hepatitis C virus NS5B polymerase thumb pocket inhibitor, the hydrochloride salt described here is an intermediate whose enantiomeric purity can plummet during ethyl ester formation if the starting material is racemic at C-1. The racemic trans-octahydrocyclopenta[c]pyrrole-1-carboxylic acid ethyl ester hydrochloride is resolved by forming a diastereomeric salt with (1R)-(−)-10-camphorsulfonic acid (CSA) in acetonitrile. A 2.0 M solution of racemic ester free base in acetonitrile is treated with 0.55 eq. of CSA at 60 °C, cooled to 5 °C over 6 h, and the resulting crystalline diastereomeric salt is filtered; the cake is repeatedly slurried in fresh acetonitrile at 70 °C (two reslurry cycles, each 3 h) to drive the diastereomeric excess above 99.5 %. The resolved salt is then neutralized with aqueous sodium carbonate to liberate the enantiopure free base, which — without purification — is immediately treated with anhydrous hydrogen chloride gas in diethyl ether to re-form the hydrochloride, isolated by filtration in 82 % yield from racemate. Chiral SFC analysis (Chiralcel OJ-H, 4.6 × 150 mm, 30 % methanol in CO₂, 3.0 mL/min, backpressure 150 bar) shows the undesired (1R,3aS,6aR)-enantiomer below 0.15 %, which is critical because the off-enantiomer occupies the NS5B palm–thumb interface with a 140° rotation of the ethyl ester vector that disrupts a key hydrogen bond to the backbone NH of Ser556, raising the K_d by a factor of 40.

Resolving the ethyl ester as the hydrochloride at this stage, instead of resolving the free acid or a crystalline amide, is driven by the unique crystal packing of the hydrochloride diastereomeric salt pair: the chloride ion forms a bifurcated hydrogen bond with the protonated pyrrolidine N–H and the C=O of the ethyl ester, a motif absent in the corresponding methyl ester or isopropyl ester, which fail to crystallize under the same conditions. The mother liquor from the CSA resolution is enriched in the (1R)-enantiomer to 92 % ee, and an epimerization/racemization protocol has been developed to recycle this stream: treatment with sodium ethoxide (0.1 eq.) in ethanol at reflux for 8 h racemizes C-1 through a ketene acetal intermediate, returning the material to ≤3 % ee and allowing a second resolution cycle. This recycling loop increases the overall process yield from racemic starting material to >70 % of the desired (1S,3aR,6aS)-enantiomer hydrochloride, satisfying the cost-of-goods targets for early-phase clinical supply.

A unique advantage of maintaining the chiral center as the hydrochloride salt — rather than the free base or a covalent conjugate — is the ease of chloride counterion metathesis when the downstream fragment must be loaded onto an ion-exchange column for capture-release purification. The hydrochloride is dissolved in water, loaded onto a strong cation-exchange resin (Dowex 50WX8, H⁺ form), and eluted with 2 M ammonia in methanol, which simultaneously removes organic-soluble neutral impurities and generates the corresponding free amine in anhydrous methanol solution. This operation has been automated on a 10-kg scale using a resin-filled column (30 cm × 15 cm ID) with UV detection at 210 nm, and the methanolic free base is telescoped directly into a hydrogenation step where the pyrrolidine ring remains unaffected, demonstrating the scaffold's inertness to Pd/C-catalyzed hydrogenation ( 5 % Pd/C, 1 atm H₂, methanol, 25 °C, 24 h) — a processing window unavailable to unsaturated pyrrole or indole analogs that would undergo ring reduction under identical conditions.